Login to Your Account

Filgotinib ball now in Abbvie court as Galapagos serves up monotherapy data

By Cormac Sheridan
Staff Writer

Tuesday, August 11, 2015

DUBLIN – Galapagos NV is in line for a $200 million payday, as positive 24-week data from a phase IIb monotherapy trial in RA testing selective JAK1 inhibitor filgotinib (GLPG0634) completed the clinical picture and formally set the clock ticking on Abbvie Inc.'s option on the program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription